Combatting COVID-19: 21 Innovative Efforts

May 15, 2020 | Blog | 0 comments

Daniel Gigante

Note: This post was co-written by Sabyasachi Dash, PhD

At the time of writing, more than 2.7 million cases of COVID-19 have been reported globally. Development of a vaccine against the novel coronavirus, SARS-CoV-2, require an investment of 12-18 months. Worse yet, the drug discovery pipeline including the critical steps of discovery of a therapeutic, pre-clinical testing, clinical testing, approval and commercialization can range in years (5-6+).

The process of identifying relevant therapeutics varies across laboratories. For instance, identification of therapeutic antibodies such as monoclonal (mAb) antibodies with desirable characteristics requires an amalgamation of high-end techniques and precision-based high-throughput platforms for testing and validation.

We’re not sharing this information to scare, but instead to inform on the challenges the healthcare industry is facing. With that in mind, below we report on 21 innovative efforts from leading and emerging players in the biotech industry to combat the COVID-19 pandemic.

1. Abbvie – Abbvie is working on a small molecule combination therapy originally used as an anti-retroviral against HIV. The combination involves Lopinavir/Ritonavir and is currently in stage III. It works by inhibiting the function of viral protease enzymes. Read more here.

2. Regeneron – Regeneron is developing mAb Therapy leveraging its proprietary VelociSuite and VelocImmune technologies. It’s currently in preclinical stages. Learn more here.

3. Ascletis – Ascletis is working on Danoprevir + Ritonavir, a stage I small molecule drug representing another class of viral protease inhibitors classically used against Hepatitis C virus. Read more here.

4. Sanofi – Sanofi is working on Plaquenil (Hydroxychloroquine), an immunosuppressive small molecule currently in preclinical stages. The drug works by increasing lysosomal pH in immune cells, inhibiting Toll like receptor, reducing inflammation, and inducing interferon production. Read more here. In addition, Sanofi is working on a DNA-based nucleic acid therapeutic that leverages recombinant DNA technology. Read more here.

5. Takeda – Takeda is working on Poly-Ab therapy (TAK-888). Currently in preclinical stages, it works using pathogen specific antibodies from recovered or vaccinated individuals. Read more here.

6. Hoth Therapeutics & Voltron Therapeutics – Hoth Therapeutics is teaming with Voltron on a self-assembling vaccine. Currently in preclinical stages, it uses a combination of chemical adjuvants which activate immune response while targeting viral factors (proteins and nucleic acids). Read more here.

7. Moderna – Moderna is working on mRNA-1273. Currently in stage I, the drug is an RNA-based nucleic acid therapeutic. Read more here.

8. CanSino Biologics – CanSinoBio is working on Ad5-nCoV. Currently in stage II, it’s a recombinant vaccine therapeutic using adenovirus based viral vector technology. Read more about it here.

9. Arcturus Therapeutics – Arcturus is working on a COVID-19 vaccine currently in preclinical stages. The vaccine is an mRNA-based nucleic acid therapeutic. Read more here.

10. AbCellera & Eli Lilly – AbCellera and Lilly have teamed up to work on an antibody therapy currently in preclinical stages. You can read more about the collaboration and their work here.

11. GSK & Clover Biopharmaceuticals – GSK and Clover are working on a protein based vaccine. It uses timer-tag technology and is currently in preclinical stages. Read more here.

12. Inovio Pharmaceuticals – Inovio is working on INO-4800, a COVID-19 vaccine currently in preclinical stages. It’s a DNA-based nucleic acid therapeutic. Read more here.

13. Nuritas – Nuritas is focusing on discovery of stable peptides to target virus-host interaction. They’re leveraging their proprietary Nuritas Peptide Finder platform. Read more here.

14. Sanofi & Regeneron – Sanofi and Regeneron make our list again, here teaming up on a mAb therapeutic, Kevzara. Currently in stage II/III, the technology works by leveraging mAb inhibiting cytokine (IL6) in host cells. Read more here.

15. Pfizer & BioNTech – Pfizer and BioNTech have teamed up to work on an mRNA vaccine (BNT162). Currently in preclinical stages, the drug is an RNA-based nucleic acid therapeutic. Read more here.

16. SOM Biotech and Ewha Womans University – SOM Biotech and Ewha are leveraging artificial intelligence based screening technology. The three candidates they’re currently working on inhibit the main protease of SARS-CoV-2. Read more here.

17. Johnson & Johnson – Johnson & Johnson is working on a COVID-19 vaccine that uses the proprietary Advac PER.66 technology. It is currently in preclinical stages. You can read more about their work here.

18. Vaccitech – Vaccitech is working on Lopinavir + Ritonavir which is currently in stage IIb. The treatment leverages small molecule inhibitors. Learn more here.

19. GSK & Vir Biotechnology – GSK makes our list again, here teaming up with Vir. The team is working on a gene-editing based mAb therapeutic, currently in preclinical stages. Read more here.

20. Gilead – Gilead is working on Remdesivir. Currently in stage III, the drug is an adenosine analogue and effectively targets the viral RNA, causing premature termination by interfering with the activity of RNA-dependent RNA polymerase enzyme. Read more here.

21. ImmunoPrecise and EVQLV – Of course, we couldn’t leave out our own efforts. ImmunoPrecise and EVQLV are working on therapeutic and vaccine candidates using high-throughput computational antibody design. Although we’ve discussed our work at length on this blog, you can check out the official release here.

This list is nowhere near exhaustive. We welcome, in the form of comments below or by contacting us directly, any new information on promising treatments for COVID-19.

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Large Pharma’s Embrace of Artificial Intelligence

The benefits of computational drug development are well known and accepted by many in the pharmaceutical space. However, since the onset of the global pandemic, consensus went from it being an interesting concept that was almost certainly the future, to something we need implemented as soon as possible. This is one of the few silver linings of the coronavirus outbreak.

The depth, vision and progress of EVQLV

Our CEO, Andrew Satz, recently spoke at Columbia University School of General Studies’ “Alumni in Action.” The subject of his talk was artificial intelligence. One of the questions posed to Andrew was what we were doing outside of coronavirus, along with the long term plans of our company

EVQLV Applies Proprietary AI Technology in Collaboration with Twist Bioscience to Discover and Validate Novel Antibody Therapies

EVQLV, Inc., an artificial intelligence-enabled technology company accelerating biologics discovery, announced today a collaboration with Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, to discover novel antibody-based therapies.

EVQLV’s Evolutionary Algorithm Explained

Brett Averso (CTO, EVQLV) and Bhoomika Kumar (SciTech intern, EVQLV) teamed up to provide a high-level overview of how EVQLV’s evolutionary algorithm works.

Andrew Satz on the Talent Finders Podcast

EVQLV’s CEO, Andrew Satz, joined Kerrin Black of the Talent Finders Podcast to discuss his entrepreneurial journey, some of the challenges facing AI for drug discovery, his legacy and much more.

Pin It on Pinterest